GYRE

Gyre Therapeutics Inc. (GYRE) | Rumor.io

Gyre Therapeutics

GYRE

Attention (50-day avg)0%

Attention rank (50-day avg)#4,296

Bullish sentiment (50-day avg)100%

Price to earnings ratio364.5

Market capitalization794.2M

Earnings per share-0.21

Dividend yield (TTM)—

Revenue (annual)116.6M

Net income (annual)9.9M

Social

What share of all stock conversation is about GYRE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 23

Gyre Therapeutics' ($GYRE) Hydronidone met the primary endpoint in a Phase 3 trial, demonstrating statistically significant fibrosis regression in treating CHB-associated liver fibrosis in China.
The company secured $20.0 million in funding to advance the treatment, with a $20 million public offering of common stock priced at $9.00 per share, a 20% discount from the previous day's close.
The funding will support the development of the MASH liver fibrosis treatment, with a cash balance of $51.2 million in 2024 and a projected loss of -$17.9 million, following a loss of -$85 million in 2023.

Generated by AI

Sentiment

Of the messages about GYRE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +70.4
Bearish	—	—	—	0% -70.4

Bullish· Jun 21

$GYRE has strong potential for continued upside, with a possible gap to $0.60 starting to get filled if it breaks $0.40.
The stock has a history of volatile moves and strong volume, indicating a possible continuation to the upside.
$GYRE has been identified as a strong uptrending stock with a possible catalyst, similar to a previous move from $0.40 to $2 in three months.

Bearish· Dec 20

The shorts in $GYRE have been squeezed, but new investors are buying in at the $8.35 area, potentially setting them up for a loss.
The company's S3 form is active, which is likely to have a negative impact on the stock.
$GYRE is trading below its VWAP (Volume-Weighted Average Price) and has a critical level at $7, indicating bearish momentum.

Generated by AI

Topics

Of the messages about GYRE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	96.36%
Analysts	—	—	—	3.64%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

May 31

$GYRE has broken $5.00 resistance and is expected to continue upwards.
The stock has strong support at $4.75 and is expected to stay above it.
A break above $5.00 could lead to a significant price increase, potentially reaching the mid 5s.

Generated by AI

Community

Of the messages about GYRE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	45.75%
Newcomers	—	—	—	54.25%

May 23

Many newcomers are focused on the recent positive Phase 3 trial data, where Gyre Therapeutics' Hydronidone demonstrated statistically significant fibrosis regression in the treatment of CHB-associated liver fibrosis in China.
New investors are excited about the company's secured funding of $20.0 million to advance its treatment for liver fibrosis, and the resulting stock offering at a discounted price.
Some newcomers are concerned about the stock's price drop, citing a 20% discount from the previous day's close, and are analyzing the company's financials, including a loss of -$17.9M in 2024 and -$85M in 2023.

Generated by AI

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that Company management will participate in the Cantor Global Healthcare Conference and the Morgan Stanley Healthcare Conference, both being held this month in New York, NY. Information about both conferences is below: Cantor Global Healthcare Confere

27d agoYahoo Finance

Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy

Detailed price information for Gyre Therapeutics Inc (GYRE-Q) from The Globe and Mail including charting and trades.

28d agotheglobeandmail.com

Gyre Therapeutics unveils capital-efficient global development strategy

Detailed price information for Gyre Therapeutics Inc (GYRE-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN)

Detailed price information for Align Technology (ALGN-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

H.C. Wainwright Sticks to Its Buy Rating for Gyre Therapeutics (GYRE)

Detailed price information for Gyre Therapeutics Inc (GYRE-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about GYRE also mention

#	Name	Attention
1	Pulmatrix Inc.PULM	0%0
2	Akari Therapeutics Plc ADRAKTX	0%0
3	Daré Bioscience, Inc.DARE	0%0
4	Adaptive Biotechnologies Corporation Common StockADPT	0%new
5	ATXS - Astria Therapeutics, Inc.	——
6	Statera Biopharma Inc.STAB	0%0
7	Vericel CorporationVCEL	0%0
8	Power Solutions International, Inc.PSIX	0%new
9	GMAN - Goldman Sachs Manufacturing Revolution ETF	——
10	CareCloud Inc.CCLD	0%new

Gyre Therapeutics Inc.

Healthcare
Biotechnology

Gyre Therapeutics Inc. is a biotechnology firm dedicated to the discovery and development of innovative therapies for unmet medical needs. Its primary function is to leverage cutting-edge research and development technologies to address complex diseases and conditions that currently lack effective treatments. Gyre Therapeutics operates within the healthcare and biomedical sectors, impacting areas such as oncology, neurology, and rare genetic disorders. The company employs a robust pipeline strategy, focusing on both in-house R&D and collaborative partnerships to accelerate drug development and facilitate clinical trials. Through strategic alliances with academic institutions and pharmaceutical companies, Gyre Therapeutics aims to enhance its scientific capabilities and expand its therapeutic portfolio. As a specialized entity in the biotech industry, Gyre Therapeutics plays a crucial role in advancing medical science, potentially transforming patient care by bringing novel bio-pharmaceutical products to the market.

Website

Location

12770 High Bluff Drive

San Diego, CA, 92130

United States

Social

What share of all stock conversation is about GYRE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 23

Gyre Therapeutics' ($GYRE) Hydronidone met the primary endpoint in a Phase 3 trial, demonstrating statistically significant fibrosis regression in treating CHB-associated liver fibrosis in China.
The company secured $20.0 million in funding to advance the treatment, with a $20 million public offering of common stock priced at $9.00 per share, a 20% discount from the previous day's close.
The funding will support the development of the MASH liver fibrosis treatment, with a cash balance of $51.2 million in 2024 and a projected loss of -$17.9 million, following a loss of -$85 million in 2023.

Generated by AI

Sentiment

Of the messages about GYRE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +70.4
Bearish	—	—	—	0% -70.4

Bullish· Jun 21

$GYRE has strong potential for continued upside, with a possible gap to $0.60 starting to get filled if it breaks $0.40.
The stock has a history of volatile moves and strong volume, indicating a possible continuation to the upside.
$GYRE has been identified as a strong uptrending stock with a possible catalyst, similar to a previous move from $0.40 to $2 in three months.

Bearish· Dec 20

The shorts in $GYRE have been squeezed, but new investors are buying in at the $8.35 area, potentially setting them up for a loss.
The company's S3 form is active, which is likely to have a negative impact on the stock.
$GYRE is trading below its VWAP (Volume-Weighted Average Price) and has a critical level at $7, indicating bearish momentum.

Generated by AI

Topics

Of the messages about GYRE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	96.36%
Analysts	—	—	—	3.64%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

May 31

$GYRE has broken $5.00 resistance and is expected to continue upwards.
The stock has strong support at $4.75 and is expected to stay above it.
A break above $5.00 could lead to a significant price increase, potentially reaching the mid 5s.

Generated by AI

Community

Of the messages about GYRE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	45.75%
Newcomers	—	—	—	54.25%

May 23

Many newcomers are focused on the recent positive Phase 3 trial data, where Gyre Therapeutics' Hydronidone demonstrated statistically significant fibrosis regression in the treatment of CHB-associated liver fibrosis in China.
New investors are excited about the company's secured funding of $20.0 million to advance its treatment for liver fibrosis, and the resulting stock offering at a discounted price.
Some newcomers are concerned about the stock's price drop, citing a 20% discount from the previous day's close, and are analyzing the company's financials, including a loss of -$17.9M in 2024 and -$85M in 2023.

Generated by AI

Gyre Therapeutics

Social

May 23

Sentiment

Bullish· Jun 21

Bearish· Dec 20

Topics

May 31

Community

May 23

News

Gyre Therapeutics at Morgan Stanley conference: cash flow funds pipeline

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy

Gyre Therapeutics unveils capital-efficient global development strategy

Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN)

H.C. Wainwright Sticks to Its Buy Rating for Gyre Therapeutics (GYRE)

Also Discussed

Gyre Therapeutics Inc.

Company Information

Location

News

Gyre Therapeutics at Morgan Stanley conference: cash flow funds pipeline

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy

Gyre Therapeutics unveils capital-efficient global development strategy

Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN)

H.C. Wainwright Sticks to Its Buy Rating for Gyre Therapeutics (GYRE)

Also Discussed

Social

May 23

Sentiment

Bullish· Jun 21

Bearish· Dec 20

Topics

May 31

Community

May 23